Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Share-based Compensation (2017 - 2025)

VYNE Therapeutics' Share-based Compensation history spans 9 years, with the latest figure at $529000.0 for Q2 2025.

  • For Q2 2025, Share-based Compensation fell 40.23% year-over-year to $529000.0; the TTM value through Jun 2025 reached $2.7 million, down 20.85%, while the annual FY2025 figure was $2.3 million, 30.12% down from the prior year.
  • Share-based Compensation reached $529000.0 in Q2 2025 per VYNE's latest filing, down from $763000.0 in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $2.4 million in Q1 2021 to a low of $529000.0 in Q2 2025.
  • Average Share-based Compensation over 5 years is $1.1 million, with a median of $889000.0 recorded in 2022.
  • The largest YoY upside for Share-based Compensation was 38.83% in 2021 against a maximum downside of 82.35% in 2021.
  • A 5-year view of Share-based Compensation shows it stood at $1.3 million in 2021, then fell by 19.89% to $1.1 million in 2022, then plummeted by 33.46% to $710000.0 in 2023, then decreased by 1.55% to $699000.0 in 2024, then decreased by 24.32% to $529000.0 in 2025.
  • Per Business Quant, the three most recent readings for VYNE's Share-based Compensation are $529000.0 (Q2 2025), $763000.0 (Q1 2025), and $699000.0 (Q4 2024).